Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY21 results · Apr–Jun 2020
Neuland Laboratories reported revenue from operations of ₹205.42 crore (up 13.5% from Q1 FY20) and net profit of ₹15.16 crore (up 165.7% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.42 | 181.01 | +13.5% | 191.64 | +7.2% |
| Other income | 0.70 | 0.52 | +34.7% | 1.78 | −60.7% |
| Total income | 206.12 | 181.53 | +13.5% | 193.42 | +6.6% |
| Profit before tax | 20.31 | 7.60 | +167.3% | 17.20 | +18.1% |
| Net profit for the period | 15.16 | 5.71 | +165.7% | (9.30) | Turned profit |
| EPS, basic (₹) | 11.82 | 4.45 | +165.6% | (7.25) | Turned profit |
| Net margin (%) | 7.4 | 3.2 | -4.9 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.42 | 181.01 | +13.5% | 191.87 | +7.1% |
| Other income | 0.70 | 0.52 | +34.7% | 1.78 | −60.7% |
| Total income | 206.12 | 181.53 | +13.5% | 193.64 | +6.4% |
| Profit before tax | 20.20 | 7.51 | +169.2% | 17.08 | +18.3% |
| Net profit for the period | 15.06 | 5.61 | +168.2% | (9.35) | Turned profit |
| EPS, basic (₹) | 11.74 | 4.38 | +168.0% | (7.29) | Turned profit |
| Net margin (%) | 7.3 | 3.1 | -4.9 |
Consolidated
- Filed with BSE
- 08 Aug 2020, 14:17 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2020, 14:17 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE